BioXcel Therapeutics Valuation
| BTAI Stock | USD 2.33 0.03 1.27% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. BioXcel Therapeutics shows a prevailing Real Value of $2.52 per share. The current price of the firm is $2.33. Our model approximates the value of BioXcel Therapeutics from analyzing the firm fundamentals such as Operating Margin of (64.21) %, return on equity of -17.67, and Shares Outstanding of 3.39 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting BioXcel Therapeutics' valuation include:
Price Book 3.9656 | Enterprise Value | Enterprise Value Ebitda (0.75) | Price Sales 3.4745 | Enterprise Value Revenue 31.8945 |
Undervalued
Today
Please note that BioXcel Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of BioXcel Therapeutics is based on 3 months time horizon. Increasing BioXcel Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioXcel Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioXcel Stock. However, BioXcel Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.33 | Real 2.52 | Target 2.81 | Hype 2.13 | Naive 1.55 |
The intrinsic value of BioXcel Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence BioXcel Therapeutics' stock price.
Estimating the potential upside or downside of BioXcel Therapeutics helps investors to forecast how BioXcel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioXcel Therapeutics more accurately as focusing exclusively on BioXcel Therapeutics' fundamentals will not take into account other important factors: When choosing an evaluation method for BioXcel Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
BioXcel Therapeutics Cash |
|
BioXcel Valuation Trend
BioXcel Therapeutics' real value analysis enables investors to forecast the earnings more efficiently. Using both BioXcel Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
BioXcel Therapeutics Total Value Analysis
BioXcel Therapeutics is currently forecasted to have valuation of 72.59 M with market capitalization of 7.91 M, debt of 101.38 M, and cash on hands of 233.45 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the BioXcel Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
72.59 M | 7.91 M | 101.38 M | 233.45 M |
BioXcel Therapeutics Investor Information
About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 32.78. BioXcel Therapeutics had not issued any dividends in recent years. The entity had 1:16 split on the 10th of February 2025. Based on the key indicators related to BioXcel Therapeutics' liquidity, profitability, solvency, and operating efficiency, BioXcel Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.BioXcel Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioXcel Therapeutics has an asset utilization ratio of 1.87 percent. This signifies that the Company is making $0.0187 for each dollar of assets. An increasing asset utilization means that BioXcel Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.BioXcel Therapeutics Ownership Allocation
BioXcel Therapeutics shows 15.38 percent of its outstanding shares held by insiders and 13.97 percent owned by other corporate entities.BioXcel Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1.38 M. Net Loss for the year was (179.05 M) with profit before overhead, payroll, taxes, and interest of 251 K.About BioXcel Therapeutics Valuation
An absolute valuation paradigm, as applied to BioXcel Stock, attempts to find the value of BioXcel Therapeutics based on its fundamental and basic technical indicators. By analyzing BioXcel Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of BioXcel Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioXcel Therapeutics. We calculate exposure to BioXcel Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioXcel Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 138 K | 144.9 K | |
| Pretax Profit Margin | (116.77) | (122.61) | |
| Operating Profit Margin | (112.03) | (117.63) | |
| Net Loss | (116.77) | (122.61) | |
| Gross Profit Margin | 0.10 | 0.10 |
BioXcel Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 29.1 M |
BioXcel Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of BioXcel Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value BioXcel we look at many different elements of the entity such as BioXcel's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BioXcel Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BioXcel Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BioXcel Therapeutics' worth.Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |